Jump to: navigation, search
Clinical data
Routes of
Oral, intravenous
ATC code
Legal status
Legal status
  • Investigational
Pharmacokinetic data
BioavailabilityGood (oral)[1]
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass354.403 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Iclaprim


Most recent articles on Iclaprim

Most cited articles on Iclaprim

Review articles on Iclaprim

Articles on Iclaprim in N Eng J Med, Lancet, BMJ


Powerpoint slides on Iclaprim

Images of Iclaprim

Photos of Iclaprim

Podcasts & MP3s on Iclaprim

Videos on Iclaprim

Evidence Based Medicine

Cochrane Collaboration on Iclaprim

Bandolier on Iclaprim

TRIP on Iclaprim

Clinical Trials

Ongoing Trials on Iclaprim at Clinical Trials.gov

Trial results on Iclaprim

Clinical Trials on Iclaprim at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Iclaprim

NICE Guidance on Iclaprim


FDA on Iclaprim

CDC on Iclaprim


Books on Iclaprim


Iclaprim in the news

Be alerted to news on Iclaprim

News trends on Iclaprim


Blogs on Iclaprim


Definitions of Iclaprim

Patient Resources / Community

Patient resources on Iclaprim

Discussion groups on Iclaprim

Patient Handouts on Iclaprim

Directions to Hospitals Treating Iclaprim

Risk calculators and risk factors for Iclaprim

Healthcare Provider Resources

Symptoms of Iclaprim

Causes & Risk Factors for Iclaprim

Diagnostic studies for Iclaprim

Treatment of Iclaprim

Continuing Medical Education (CME)

CME Programs on Iclaprim


Iclaprim en Espanol

Iclaprim en Francais


Iclaprim in the Marketplace

Patents on Iclaprim

Experimental / Informatics

List of terms related to Iclaprim

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Iclaprim (INN), codenamed AR-100 and RO-48-2622, is a diaminopyrimidine dihydrofolate reductase (DHFR)-inhibiting extended-spectrum antibiotic active against gram positive organisms being developed for the treatment of complicated skin and soft tissue infections caused by antibiotic-resistant bacteria.[2] It is structurally related to trimethoprim. In Phase III clinical trials, intravenously-administered iclaprim was found to be as effective as and better tolerated than linezolid in people with skin and soft tissue infections, many caused by methicillin-resistant Staphylococcus aureus (MRSA).[3][4] In vitro, iclaprim is highly active against MRSA, vancomycin-resistant Staphylococcus aureus (VRSA), strains of Streptococcus pneumoniae resistant to several common antibiotics, and some Gram-negative bacteria.[1]

A new drug application for iclaprim was filed with the U.S. Food and Drug Administration in March 2008,[3] and a marketing authorisation application (MAA) was accepted by the European Medicines Agency on August 21, 2008. Phase II clinical trials are being conducted to assess whether iclaprim can be taken by mouth as well as intravenously and whether it is effective for the treatment of hospital-acquired pneumonia.[4][5]

Iclaprim was granted fast track status by the FDA,[6] but approval of the drug was eventually declined in 2009[7] and no further development has taken place since then.


  1. 1.0 1.1 Kohlhoff SA, Sharma R (September 2007). "Iclaprim". Expert Opin Investig Drugs. 16 (9): 1441–8. doi:10.1517/13543784.16.9.1441. PMID 17714029.
  2. Kohlhoff, SA; Sharma, R (September 2007). "Iclaprim". Expert Opinion on Investigational Drugs. 16 (9): 1441–8. doi:10.1517/13543784.16.9.1441. PMID 17714029.
  3. 3.0 3.1 "Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections" (Press release). Reuters. March 19, 2008. Retrieved 2008-08-24.
  4. 4.0 4.1 "Arpida's iclaprim MAA Accepted for Review by EMEA" (Press release). PR Newswire. August 21, 2008. Retrieved 2008-08-24.
  5. Peppard, WJ; Schuenke, CD (February 2008). "Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections". Current Opinion on Investigational Drugs. 9 (2): 210–25. PMID 18246524.
  6. Morgan A, Cofer C, Stevens DL (March 2009). "Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections". Future Microbiol. 4 (2): 131–44. doi:10.2217/17460913.4.2.131. PMID 19257839.
  7. Arpida receives FDA complete response letter for Iclaprim

Further reading